Search the Newsreel

Cytek Bio stock trades steadily as Q1 2026 growth and margin profile frame investor focus

Cytek Biosciences Inc. (CTKB) stock is trading steadily, reflecting a combination of revenue growth, improving margins, and an expanding installed base of cell analysis instruments. The company's Q1 2026 performance highlighted rising revenue driven by spectral flow cytometry instruments and associated reagents, alongside robust …

Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement

Cytek Biosciences has opened a new innovation center in Bellevue, Washington, relocating its previous Seattle-area operations. This facility is designed to support research and development, strengthen collaboration, and enhance customer engagement, featuring R&D laboratories, instrument service training areas, customer demonstration spaces, and assembly and …

Cytek Biosciences (Nasdaq: CTKB) sets severance and consulting terms

Cytek Biosciences has detailed the separation terms for its former Chief Legal Officer and Corporate Secretary, Valerie Barnett, whose tenure ended on June 29, 2026. The agreement includes a one-time severance payment of $365,775.12 and COBRA premium coverage, with enhanced benefits if a Change …

Cytek's Valerie Barnett exits as Chief Legal Officer; consulting role agreed

Valerie Barnett's role as Chief Legal Officer and Corporate Secretary at Cytek terminated on June 29, 2026. She subsequently entered into a severance and consulting agreement in July 2026, which includes a one-time lump sum payment, COBRA premiums, and specific terms for her consulting …

Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets

Cytek Biosciences Gains 1.7% as Stock Holds Above Support; Resistance Ahead - Break of Structure

Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth

Stephens cuts Cytek Biosciences stock price target on elevated costs

Cytek Biosciences (CTKB) Stock Falls on Q1 2026 Earnings

Cytek Biosciences Reports First Quarter 2026 Financial Results

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates

Cytek Biosciences (CTKB) Inspiring Confidence With Aurora CS System Updates

Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Cytek Biosciences (CTKB) Stock Price, News & Analysis